Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.

Lawrence MG, Obinata D, Sandhu S, Selth LA, Wong SQ, Porter LH, Lister N, Pook D, Pezaro CJ, Goode DL, Rebello RJ, Clark AK, Papargiris M, Van Gramberg J, Hanson AR, Banks P, Wang H, Niranjan B, Keerthikumar S, Hedwards S, Huglo A, Yang R, Henzler C, Li Y, Lopez-Campos F, Castro E, Toivanen R, Azad A, Bolton D, Goad J, Grummet J, Harewood L, Kourambas J, Lawrentschuk N, Moon D, Murphy DG, Sengupta S, Snow R, Thorne H, Mitchell C, Pedersen J, Clouston D, Norden S, Ryan A, Dehm SM, Tilley WD, Pearson RB, Hannan RD, Frydenberg M, Furic L, Taylor RA, Risbridger GP.

Eur Urol. 2018 Nov;74(5):562-572. doi: 10.1016/j.eururo.2018.06.020. Epub 2018 Jul 23.

PMID:
30049486
2.

AMP-activated protein kinase selectively inhibited by the type II inhibitor SBI-0206965.

Dite TA, Langendorf CG, Hoque A, Galic S, Rebello RJ, Ovens AJ, Lindqvist LM, Ngoei KRW, Ling NXY, Furic L, Kemp BE, Scott JW, Oakhill JS.

J Biol Chem. 2018 Jun 8;293(23):8874-8885. doi: 10.1074/jbc.RA118.003547. Epub 2018 Apr 25.

PMID:
29695504
3.

Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth.

Pearson HB, Li J, Meniel VS, Fennell CM, Waring P, Montgomery KG, Rebello RJ, Macpherson AA, Koushyar S, Furic L, Cullinane C, Clarkson RW, Smalley MJ, Simpson KJ, Phesse TJ, Shepherd PR, Humbert PO, Sansom OJ, Phillips WA.

Cancer Discov. 2018 Jun;8(6):764-779. doi: 10.1158/2159-8290.CD-17-0867. Epub 2018 Mar 26.

PMID:
29581176
4.

Epididymal cysteine-rich secretory proteins are required for epididymal sperm maturation and optimal sperm function.

Hu J, Merriner DJ, O'Connor AE, Houston BJ, Furic L, Hedger MP, O'Bryan MK.

Mol Hum Reprod. 2018 Mar 1;24(3):111-122. doi: 10.1093/molehr/gay001.

PMID:
29361143
5.

Cross-talk between protein synthesis, energy metabolism and autophagy in cancer.

Lindqvist LM, Tandoc K, Topisirovic I, Furic L.

Curr Opin Genet Dev. 2018 Feb;48:104-111. doi: 10.1016/j.gde.2017.11.003. Epub 2017 Nov 25. Review.

6.

PIM activity in tumours: A key node of therapy resistance.

Rebello RJ, Huglo AV, Furic L.

Adv Biol Regul. 2018 Jan;67:163-169. doi: 10.1016/j.jbior.2017.10.010. Epub 2017 Oct 22. Review.

PMID:
29111105
7.

mTOR-sensitive translation: Cleared fog reveals more trees.

Masvidal L, Hulea L, Furic L, Topisirovic I, Larsson O.

RNA Biol. 2017 Oct 3;14(10):1299-1305. doi: 10.1080/15476286.2017.1290041. Epub 2017 Feb 10. Review.

8.

Therapeutic Approaches Targeting MYC-Driven Prostate Cancer.

Rebello RJ, Pearson RB, Hannan RD, Furic L.

Genes (Basel). 2017 Feb 16;8(2). pii: E71. doi: 10.3390/genes8020071. Review.

9.

The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.

Rebello RJ, Kusnadi E, Cameron DP, Pearson HB, Lesmana A, Devlin JR, Drygin D, Clark AK, Porter L, Pedersen J, Sandhu S, Risbridger GP, Pearson RB, Hannan RD, Furic L.

Clin Cancer Res. 2016 Nov 15;22(22):5539-5552. doi: 10.1158/1078-0432.CCR-16-0124. Epub 2016 Aug 2.

10.

mTORC1 and CK2 coordinate ternary and eIF4F complex assembly.

Gandin V, Masvidal L, Cargnello M, Gyenis L, McLaughlan S, Cai Y, Tenkerian C, Morita M, Balanathan P, Jean-Jean O, Stambolic V, Trost M, Furic L, Larose L, Koromilas AE, Asano K, Litchfield D, Larsson O, Topisirovic I.

Nat Commun. 2016 Apr 4;7:11127. doi: 10.1038/ncomms11127.

11.

nanoCAGE reveals 5' UTR features that define specific modes of translation of functionally related MTOR-sensitive mRNAs.

Gandin V, Masvidal L, Hulea L, Gravel SP, Cargnello M, McLaughlan S, Cai Y, Balanathan P, Morita M, Rajakumar A, Furic L, Pollak M, Porco JA Jr, St-Pierre J, Pelletier J, Larsson O, Topisirovic I.

Genome Res. 2016 May;26(5):636-48. doi: 10.1101/gr.197566.115. Epub 2016 Mar 16.

12.

From Sphingosine Kinase to Dihydroceramide Desaturase: A Structure-Activity Relationship (SAR) Study of the Enzyme Inhibitory and Anticancer Activity of 4-((4-(4-Chlorophenyl)thiazol-2-yl)amino)phenol (SKI-II).

Aurelio L, Scullino CV, Pitman MR, Sexton A, Oliver V, Davies L, Rebello RJ, Furic L, Creek DJ, Pitson SM, Flynn BL.

J Med Chem. 2016 Feb 11;59(3):965-84. doi: 10.1021/acs.jmedchem.5b01439. Epub 2016 Feb 3.

PMID:
26780304
13.

Pro-tumorigenic role of ERα in prostate cancer cells.

Furic L, Lawrence MG, Risbridger GP.

Aging (Albany NY). 2015 Jun;7(6):356-7. No abstract available.

PMID:
26143334
Free PMC Article
14.

Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity.

Takizawa I, Lawrence MG, Balanathan P, Rebello R, Pearson HB, Garg E, Pedersen J, Pouliot N, Nadon R, Watt MJ, Taylor RA, Humbert P, Topisirovic I, Larsson O, Risbridger GP, Furic L.

Oncotarget. 2015 Jan 20;6(2):604-16.

15.

A pro-tumourigenic loop at the human prostate tumour interface orchestrated by oestrogen, CXCL12 and mast cell recruitment.

Ellem SJ, Taylor RA, Furic L, Larsson O, Frydenberg M, Pook D, Pedersen J, Cawsey B, Trotta A, Need E, Buchanan G, Risbridger GP.

J Pathol. 2014 Sep;234(1):86-98. doi: 10.1002/path.4386. Epub 2014 Jul 9.

PMID:
25042571
16.

Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3.

Robichaud N, del Rincon SV, Huor B, Alain T, Petruccelli LA, Hearnden J, Goncalves C, Grotegut S, Spruck CH, Furic L, Larsson O, Muller WJ, Miller WH, Sonenberg N.

Oncogene. 2015 Apr 16;34(16):2032-42. doi: 10.1038/onc.2014.146. Epub 2014 Jun 9.

17.

Hedgehog signaling is active in human prostate cancer stroma and regulates proliferation and differentiation of adjacent epithelium.

Wilkinson SE, Furic L, Buchanan G, Larsson O, Pedersen J, Frydenberg M, Risbridger GP, Taylor RA.

Prostate. 2013 Dec;73(16):1810-23. doi: 10.1002/pros.22720. Epub 2013 Sep 16.

PMID:
24105601
18.

Estrogen receptor β activation impairs prostatic regeneration by inducing apoptosis in murine and human stem/progenitor enriched cell populations.

Hussain S, Lawrence MG, Taylor RA, Lo CY; APC BioResource, Frydenberg M, Ellem SJ, Furic L, Risbridger GP.

PLoS One. 2012;7(7):e40732. doi: 10.1371/journal.pone.0040732. Epub 2012 Jul 10.

19.

Translational control of the activation of transcription factor NF-κB and production of type I interferon by phosphorylation of the translation factor eIF4E.

Herdy B, Jaramillo M, Svitkin YV, Rosenfeld AB, Kobayashi M, Walsh D, Alain T, Sean P, Robichaud N, Topisirovic I, Furic L, Dowling RJO, Sylvestre A, Rong L, Colina R, Costa-Mattioli M, Fritz JH, Olivier M, Brown E, Mohr I, Sonenberg N.

Nat Immunol. 2012 Apr 29;13(6):543-550. doi: 10.1038/ni.2291.

20.

Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.

Konicek BW, Stephens JR, McNulty AM, Robichaud N, Peery RB, Dumstorf CA, Dowless MS, Iversen PW, Parsons S, Ellis KE, McCann DJ, Pelletier J, Furic L, Yingling JM, Stancato LF, Sonenberg N, Graff JR.

Cancer Res. 2011 Mar 1;71(5):1849-57. doi: 10.1158/0008-5472.CAN-10-3298. Epub 2011 Jan 13.

21.

Modulation of 4E-BP1 function as a critical determinant of enzastaurin-induced apoptosis.

Dumstorf CA, Konicek BW, McNulty AM, Parsons SH, Furic L, Sonenberg N, Graff JR.

Mol Cancer Ther. 2010 Dec;9(12):3158-63. doi: 10.1158/1535-7163.MCT-10-0413. Epub 2010 Oct 22.

22.

eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression.

Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, Brueschke A, Petroulakis E, Robichaud N, Pollak M, Gaboury LA, Pandolfi PP, Saad F, Sonenberg N.

Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14134-9. doi: 10.1073/pnas.1005320107. Epub 2010 Aug 2.

23.

p53-dependent translational control of senescence and transformation via 4E-BPs.

Petroulakis E, Parsyan A, Dowling RJ, LeBacquer O, Martineau Y, Bidinosti M, Larsson O, Alain T, Rong L, Mamane Y, Paquet M, Furic L, Topisirovic I, Shahbazian D, Livingstone M, Costa-Mattioli M, Teodoro JG, Sonenberg N.

Cancer Cell. 2009 Nov 6;16(5):439-46. doi: 10.1016/j.ccr.2009.09.025.

24.
26.

Staufen1 regulates diverse classes of mammalian transcripts.

Kim YK, Furic L, Parisien M, Major F, DesGroseillers L, Maquat LE.

EMBO J. 2007 Jun 6;26(11):2670-81. Epub 2007 May 17.

27.

Staufen1 is imported into the nucleolus via a bipartite nuclear localization signal and several modulatory determinants.

Martel C, Macchi P, Furic L, Kiebler MA, Desgroseillers L.

Biochem J. 2006 Jan 1;393(Pt 1):245-54.

28.

[Post-transcriptional regulation of gene expression: another role for Staufen1].

Furic L, Desgroseillers L.

Med Sci (Paris). 2005 Jun-Jul;21(6-7):571-3. French. No abstract available.

29.

Mammalian Staufen1 recruits Upf1 to specific mRNA 3'UTRs so as to elicit mRNA decay.

Kim YK, Furic L, Desgroseillers L, Maquat LE.

Cell. 2005 Jan 28;120(2):195-208.

30.

Localization of the RNA-binding proteins Staufen1 and Staufen2 at the mammalian neuromuscular junction.

Bélanger G, Stocksley MA, Vandromme M, Schaeffer L, Furic L, DesGroseillers L, Jasmin BJ.

J Neurochem. 2003 Aug;86(3):669-77.

31.

Staufen2 isoforms localize to the somatodendritic domain of neurons and interact with different organelles.

Duchaîne TF, Hemraj I, Furic L, Deitinghoff A, Kiebler MA, DesGroseillers L.

J Cell Sci. 2002 Aug 15;115(Pt 16):3285-95.

Supplemental Content

Support Center